Atlas FDA

Predicate Research Report · generated 2026-08-23 · Print / save as PDF · Save to account

Ascensia Diabetes Care U.S., Inc. · Predicate Candidate Screening

7 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

67 daysmedian FDA review time
143 days90th percentile
7clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K250813MICROLET®NEXT 2 Lancing DeviceAscensia Diabetes Care U.S., Inc.2025-05-14580
K241787CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR®Ascensia Diabetes Care U.S., Inc.2024-08-27670
K241810MICROLET®NEXT LancetAscensia Diabetes Care U.S., Inc.2024-08-15550
K223293CONTOUR® NEXT GEN Blood Glucose Monitoring SystemAscensia Diabetes Care U.S., Inc.2022-11-18230
K220633MICROLET NEXT lancing device, MICROLET LancetAscensia Diabetes Care U.S., Inc.2022-06-03910
K162336Contour Next EZ Blood Glucose Monitoring SystemAscensia Diabetes Care U.S., Inc.2017-01-121430
K160430Contour Next Link Wireless Blood Glucose Monitoring System, Ascensia Diabetes Care U.S., Inc.2016-06-241290

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams: atlasbyauro.com/fda